INS and type 2 diabetes mellitus: The individuals in the C4 group had fewer years since their T2D diagnosis, slightly lower baseline HbA1c, and were less likely to use biguanides, sulfonylureas and thiazolidinediones, and insulin than non-C4 individuals [2].